D Ng1, L Churilov2, P Mitchell1, R Dowling1, B Yan3,4. 1. From the Department of Radiology (D.N., P.M., R.D., B.Y.). 2. Statistics and Decision Analysis (L.C.), Florey Institute of Neuroscience and Mental Health, Heidelberg, Victoria, Australia. 3. From the Department of Radiology (D.N., P.M., R.D., B.Y.) bernard.yan@mh.org.au. 4. Melbourne Brain Centre (B.Y.), University of Melbourne, Royal Melbourne Hospital, Parkville, Victoria, Australia.
Abstract
BACKGROUND AND PURPOSE: Hematoma expansion is an independent determinant of poor clinical outcome in intracerebral hemorrhage. Although the "spot sign" predicts hematoma expansion, the identification requires CT angiography, which limits its general accessibility in some hospital settings. Noncontrast CT, without the need for CT angiography, may identify sites of active extravasation, termed the "swirl sign." We aimed to determine the association of the swirl sign with hematoma expansion. MATERIALS AND METHODS: Patients with spontaneous intracerebral hemorrhage between 2007 and 2014 who underwent an initial and subsequent noncontrast CT at a single center were retrospectively identified. The swirl sign, on noncontrast CT, was defined as iso- or hypodensity within a hyperdense region that extended across 2 contiguous 5-mm axial CT sections. RESULTS: A total of 212 patients met the inclusion criteria. The swirl sign was identified in 91 patients with excellent interobserver agreement (κ = 0.87). The swirl sign was associated with larger initial hematoma (P < .001) and earlier initial CT (P < .001) and hematoma expansion (P = .028). Multivariable regression modeling demonstrated that if one assumed similar initial hematoma volume, onset-to-first scan, and time between CT scans, the median absolute hematoma growth was 5.77 mL (95% CI, 2.37-9.18 mL; P = .001) and relative growth was 35.6% (95% CI, 18.5%-52.6%; P < .001) higher in patients with the swirl sign compared with those without. CONCLUSIONS: The NCCT swirl sign was reliably identified and is associated with hematoma expansion. We propose that the swirl sign be included in risk stratification of intracerebral hemorrhage and considered for inclusion in clinical trials.
BACKGROUND AND PURPOSE:Hematoma expansion is an independent determinant of poor clinical outcome in intracerebral hemorrhage. Although the "spot sign" predicts hematoma expansion, the identification requires CT angiography, which limits its general accessibility in some hospital settings. Noncontrast CT, without the need for CT angiography, may identify sites of active extravasation, termed the "swirl sign." We aimed to determine the association of the swirl sign with hematoma expansion. MATERIALS AND METHODS:Patients with spontaneous intracerebral hemorrhage between 2007 and 2014 who underwent an initial and subsequent noncontrast CT at a single center were retrospectively identified. The swirl sign, on noncontrast CT, was defined as iso- or hypodensity within a hyperdense region that extended across 2 contiguous 5-mm axial CT sections. RESULTS: A total of 212 patients met the inclusion criteria. The swirl sign was identified in 91 patients with excellent interobserver agreement (κ = 0.87). The swirl sign was associated with larger initial hematoma (P < .001) and earlier initial CT (P < .001) and hematoma expansion (P = .028). Multivariable regression modeling demonstrated that if one assumed similar initial hematoma volume, onset-to-first scan, and time between CT scans, the median absolute hematoma growth was 5.77 mL (95% CI, 2.37-9.18 mL; P = .001) and relative growth was 35.6% (95% CI, 18.5%-52.6%; P < .001) higher in patients with the swirl sign compared with those without. CONCLUSIONS: The NCCT swirl sign was reliably identified and is associated with hematoma expansion. We propose that the swirl sign be included in risk stratification of intracerebral hemorrhage and considered for inclusion in clinical trials.
Authors: Andrew M Demchuk; Dar Dowlatshahi; David Rodriguez-Luna; Carlos A Molina; Yolanda Silva Blas; Imanuel Dzialowski; Adam Kobayashi; Jean-Martin Boulanger; Cheemun Lum; Gord Gubitz; Vasantha Padma; Jayanta Roy; Carlos S Kase; Jayme Kosior; Rohit Bhatia; Sarah Tymchuk; Suresh Subramaniam; David J Gladstone; Michael D Hill; Richard I Aviv Journal: Lancet Neurol Date: 2012-03-08 Impact factor: 44.182
Authors: M L Flaherty; M Haverbusch; P Sekar; B Kissela; D Kleindorfer; C J Moomaw; L Sauerbeck; A Schneider; J P Broderick; D Woo Journal: Neurology Date: 2006-04-25 Impact factor: 9.910
Authors: Joseph P Broderick; Michael N Diringer; Michael D Hill; Nikolai C Brun; Stephan A Mayer; Thorsten Steiner; Brett E Skolnick; Stephen M Davis Journal: Stroke Date: 2007-02-08 Impact factor: 7.914
Authors: Josser E Delgado Almandoz; Albert J Yoo; Michael J Stone; Pamela W Schaefer; Joshua N Goldstein; Jonathan Rosand; Alexandra Oleinik; Michael H Lev; R Gilberto Gonzalez; Javier M Romero Journal: Stroke Date: 2009-07-02 Impact factor: 7.914
Authors: Minmin Ma; Atte Meretoja; Leonid Churilov; Gagan J Sharma; Søren Christensen; Xinfeng Liu; Louise Weir; Stephen M Davis; Bernard Yan Journal: J Neurol Sci Date: 2013-07-30 Impact factor: 3.181
Authors: Stefan P Haider; Adnan I Qureshi; Abhi Jain; Hishan Tharmaseelan; Elisa R Berson; Tal Zeevi; Shahram Majidi; Christopher G Filippi; Simon Iseke; Moritz Gross; Julian N Acosta; Ajay Malhotra; Jennifer A Kim; Lauren H Sansing; Guido J Falcone; Kevin N Sheth; Seyedmehdi Payabvash Journal: Eur J Neurol Date: 2021-07-18 Impact factor: 6.288